The need for biosimilars in the USA: Obstacles and solutions
Biologics are of major importance to the US medical system. However the
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Biologics are of major importance to the US medical system. However the
The author will talk on the history of use of living organisms
Access is a function of accessibility (or reach), availability, acceptability (quality) and
The introduction of the Biopharmaceutics Classification System (BCS) in 1995 was the
One key factor to regulate the development of biosimilars is to reduce
Governments, health payers and social and health reforms combined with increased incidence
Bioavailability is the rate and extent (amount) of absorption of unchanged drug
Biosimilars also known as follow-on biologics are biologic medical products, whose
The market of biologics is growing at nearly twice the rate of
New Biologic? is being developed as a biosimilar version of ?Comparator?. The
The regulatory landscape for the development of biosimilars in the US and
In the light of the expiration of a number of patents on
Biosimilars offer big opportunities in the global market but with associated great
Biosimilars has been the topic of contention, enthusiasm and research for the
Quality attributes of a biologic product have the potential to impact pharmacological
Keeping in view the heterogeneity of tumors, there is a need to
Whenever an innovator molecule is launched in the sector of pharmaceuticals, it
The most important issues facing global drug regulators are the scientific and
Biological comparability of biosimilars is closely related to the clinical effectiveness. Potency
Unwanted immunogenicity is a significant issue affecting most biotherapeutic products, including biosimilars
Biosimilars have been in the market for years driven by early products
Medicinal plants are enriched with several active constituents responsible for their biopotency
Therapeutic proteins and antibodies are one of the most important and rapidly
Biosimilar studies need to be conducted according to ICH-GCP and international
The development of biosimilars for emerging markets faces many challenges, including abbreviated
For authors and organisers
Find the right journal for your paper and submit your manuscript.